Corpus overview


Overview

MeSH Disease

Human Phenotype

Hypertension (443)

Fever (98)

Cough (85)

Pneumonia (79)

Obesity (73)


Transmission

Seroprevalence
    displaying 51 - 60 records in total 443
    records per page




    The Association Between Presence of Comorbidities and COVID-19 Severity; A Systematic Review and Meta-Analysis

    Authors: Maryam Honardoost; Laila Janani; Rokhsareh Aghili; Zahra Emami; Mohammad E Khamseh

    id:10.20944/preprints202008.0475.v1 Date: 2020-08-21 Source: Preprints.org

    Results: A total of 6270 individuals were assessed (1615 severe and 4655 non-severe patients). The median age TRANS was 63 (95% CI: 49-74) and 47 (95% CI: 19-63) years in the severe and non-severe groups, respectively. Moreover, about 41% of patients had comorbidities. Severity was higher in patients with history of cerebrovascular disease MESHD: OR 4.85 (95% CI: 3.11-7.57). The odds of being in severe group increase by 4.81(95% CI: 3.43-6.74) for history of cardiovascular disease MESHD ( CVD MESHD). This was 4.19 (95% CI: 2.84-6.19) for chronic lung disease HP chronic lung disease MESHD and 3.18, 95% CI: 2.09-4.82 for cancer MESHD .The odds ratio of a diabetes MESHD and hypertension HP hypertension MESHD were 2.61 (95% CI: 2.02-3.3), and 2.37( 95% CI: 1.80-3.13) respectively.

    Clinico-epidemiological characteristics of asymptomatic TRANS and symptomatic COVID-19-positive patients in Bangladesh

    Authors: Mohammad Jahid Hasan; Sayeda Mukta Chowdhury; Md Abdullah Saeed Khan; Monjur Rahaman; Jannatul Fardous; Tanjir Adit; Mustafizur Rahman; Md. Tarek Hossain; Shakila Yesmin; Enayetur Raheem; Mohammad Robed Amin; Juan Ruiz; Peter Hart; Hemant Kulkarni; Tracy Hussell; John R. Grainger; Craig J Smith; Stuart M Allan; Michelle M. Lister; Hannah C. Howson-Wells; Edward C Holmes; Matthew W. Loose; Jonathan K. Ball; C. Patrick McClure; - The COVID-19 Genomics UK consortium study group; Shi Chen

    doi:10.1101/2020.08.18.20177089 Date: 2020-08-21 Source: medRxiv

    Background: As of August 15, 2020, Bangladesh lost 3591 lives since the first Coronavirus disease 2019 (COVID-19) case announced on March 8. The objective of the study was to report the clinical manifestation of both symptomatic and asymptomatic TRANS COVID-19-positive patients. Methods: A online-based cross-sectional survey was conducted for initial recruitment of participants with subsequent telephone interview by the three trained physicians in 237 adults TRANS with confirmed COVID-19 infection MESHD in Bangladesh. The study period was between 27 April to 26th May, 2020. Consent was ensured before commencing the interview. Collected data were entered in a predesigned case report form and subsequently analyzed by SPSS 20. Results: The mean age TRANS at presentation was 41.59 (13.73 SD) years and most of the cases were male TRANS (73%). A total of 90.29% of patients reside in urban areas. Among the positive cases, 13.1% (n=31) were asymptomatic TRANS. Asymptomatic TRANS cases were significantly more common in households with 2 to 4 members (p=.008). Both symptomatic and asymptomatic TRANS patients shared similar ages TRANS of presentation (p=0.23), gender TRANS differences (p=0.30), and comorbidities (p=0.11). Only 5.3% of patients received ICU care during their treatment. The most frequent presentation was fever HP fever MESHD (88.3%), followed by cough HP (69.9%), chest pain HP chest pain MESHD (34.5%), body ache MESHD (31.1%), and sore throat (30.1%). Thirty-nine percent (n=92) of the patients had comorbidities, with diabetes MESHD and hypertension HP hypertension MESHD being the most frequently observed. Conclusion: There has been an upsurge in COVID-19 cases in Bangladesh. Patients were mostly middle- aged TRANS and male TRANS. Typical presentations were fever HP fever MESHD and cough HP cough MESHD. Maintenance of social distancing and increased testing are required to meet the current public health challenge.

    Effect of COVID-19 on noise pollution change in Dublin, Ireland

    Authors: Bidroha Basu; Enda Murphy; Anna Molter; Arunima Sarkar Basu; Srikanta Sannigrahi; Miguel Belmonte; Francesco Pilla

    id:2008.08993v1 Date: 2020-08-20 Source: arXiv

    Noise pollution is considered to be the third most hazardous pollution after air and water pollution by the World Health Organization (WHO). Short as well as long-term exposure to noise pollution has several adverse effects on humans, ranging from psychiatric disorders MESHD such as anxiety HP anxiety MESHD and depression MESHD, hypertension HP hypertension MESHD, hormonal dysfunction, and blood SERO pressure rise leading to cardiovascular disease MESHD. One of the major sources of noise pollution is road traffic. The WHO reports that around 40% of Europe's population are currently exposed to high noise levels. This study investigates noise pollution in Dublin, Ireland before and after the lockdown imposed as a result of the COVID-19 pandemic. The analysis was performed using 2020 hourly data from 12 noise monitoring stations. More than 80% of stations recorded high noise levels for more that 60% of the time before the lockdown in Dublin. However, a significant reduction in average and minimum noise levels was observed at all stations during the lockdown period and this can be attributed to reductions in both road and air traffic movements.

    Assessment of the Presence of Symptoms, Individual Protection Measures (IPM) and Suspect Screening Measures (SSM) of COVID-19 in Federal Police Officers from a Regional Police Station in Brazil

    Authors: Jefferson Aparecido Dias; Eduardo Federighi Baisi Chagas; Cláudia Rucco Penteado Detregiachi; Fernanda Mesquita Serva; Piero Biteli; Claudemir Gregório Mendes; Elídia Fabiana de Souza Xavier; Carlos Francisco Bitencourt Jorge; Tereza Lais Menegucci Zutin; Mateus Cezar dos Santos; Daniela Vieira Buchaim; Rogério Leone Buchaim

    id:10.20944/preprints202008.0408.v1 Date: 2020-08-19 Source: Preprints.org

    The coronavirus of severe acute respiratory syndrome MESHD 2 (SARS-CoV-2), known as COVID-19, has spread rapidly around the world, leading to social detachment MESHD and the home office replacing face-to-face work. The performance SERO of police officers faces limitations to the new requirements, while recognizing the need to ensure health and quality of life. Thus, the present study aimed to verify the panorama of the spread of COVID-19 among federal police officers by analyzing the presence of symptoms, individual protection measures (IPM), suspect screening measures (SSM) and examination for total antibodies SERO (IgA, IgG and IgM). For this, data were collected through a questionnaire customized for this situation, blood SERO for serological testing SERO and measurements of clinical data from 56 federal police officers in the municipality of Marília (São Paulo, Brazil). There was no positive result in the Anti-SARS-CoV-2 serological test SERO in any sample participant. The mean value of the Body Mass Index (27.2 ± 5.4 kg / m2) suggests overweight HP and obesity HP obesity MESHD, in addition to the presence of hypertension HP hypertension MESHD in 16.1%, diabetes MESHD in 3.6%, asthma HP asthma MESHD in 3.6 % and obesity HP obesity MESHD by 25%, which represents an important risk of complications for COVID-19. The use of a mask is the most frequent IPM (96.4%) and most of the sample has used a cloth or home mask (90.9%). However, 47.3% have not performed the correct cleaning of the masks and 5.5% have not taken any care with mask hygiene. It can be concluded that care in relation to the professional activities of federal police to date has prevented the spread of SARS-CoV-2 and that they must be maintained or increased because risk factors, which involve quality of life and worsening of the contamination condition, were detected in the participants.

    Number of Pre-Existing Comorbidities and Prognosis of COVID-19: A Retrospective Cohort Study

    Authors: Danrong Jing; Juan Su; Lin Ye; Yan Zhang; Yanhui Cui; Hong Liu; Minxue Shen; Pinhua Pan; Xiang Chen

    doi:10.21203/rs.3.rs-61563/v1 Date: 2020-08-18 Source: ResearchSquare

    Background: Though many studies have described the association of COVID-19 and different kinds of noncommunicable chronic diseases, information with the combine effects of comorbidities to COVID-19 patients have not been well characterized yet. The aim of this study was to examine the associations of numbers of comorbidities with critical type and death of COVID-19.Methods: This was a single-centered retrospective study among patients with COVID-19. All patients with COVID-19 enrolled in this study were diagnosed according to World Health Organization interim guidance. Six different kinds of noncommunicable chronic diseases were included in this study. The logistic regression model was used to estimate the fixed effect of numbers of comorbidities on critical type or death MESHD, adjusting for potential confounders.Results: In total, 475 COVID-19 patients were enrolled in our study, included 234 females TRANS and 241 males TRANS. Hypertension HP Hypertension MESHD was the most frequent type (162 [34.1%] of 475 patients). Patients with two or more comorbidities have higher risk of critical type (OR 3.072, 95% CI [1.581, 5.970], p=0.001) and death MESHD (OR 5.538, 95% CI [1.577, 19.451], p=0.008) compared to patients without comorbidities. And the results were similar after adjusting for age TRANS and gender TRANS in critical type (OR 2.021, 95% CI [1.002–4.077], p=0.049) and death MESHD (OR 3.653, 95% CI [0.989, 13.494], p=0.052).Conclusions: The number of comorbidities was an independent risk factor for critical type and death in COVID-19 patients.

    Risk factors associated with morbidity and mortality outcomes of COVID-19 patients on the 14th and 28th day of the disease course: a retrospective cohort study in Bangladesh

    Authors: Md. Ziaul Islam; Baizid Khoorshid Riaz; ANM Shamsul Islam; Fahmida Khanam; Jabin Akhter; Rafaat Choudhury; Nasreen Farhana; Mohammad Jamal Uddin; Syeda Sumaiya Efa; Pedro A Piedra; Larry R Ellingsworth; Gregory Glenn; Gale Smith; Joseph Torresi; Weisan Chen; Linda Wakim; Allen Cheng; Jan Petersen; Jamie Rossjohn; Adam K Wheatley; Stephen Kent; Louise Rowntree; Katherine Kedzierska; Mengge Lyu; Guixiang Xiao; Xia Xu; Weigang Ge; Jiale He; Jun Fan; Junhua Wu; Meng Luo; Xiaona Chang; Huaxiong Pan; Xue Cai; Junjie Zhou; Jing Yu; Huanhuan Gao; Mingxing Xie; Sihua Wang; Guan Ruan; Hao Chen; Hua Su; Heng Mei; Danju Luo; Dashi Zhao; Fei Xu; Yan Li; Yi Zhu; Jiahong Xia; Yu Hu; Tiannan Guo

    doi:10.1101/2020.08.17.20176586 Date: 2020-08-18 Source: medRxiv

    Diverse risk factors intercede the outcomes of COVID-19. We conducted this retrospective cohort study to identify the risk factors associated with morbidity and mortality outcomes with a cohort of 1016 COVID-19 patients diagnosed in May 2020. Data were collected by telephone-interview and reviewing records using a questionnaire and checklist. Morbidity (64.4% Vs. 6.0%) and mortality (2.3% Vs. 2.5%) outcomes varied between the 14th and 28th day. Morbidity risk factors included chronic obstructive pulmonary disease HP obstructive pulmonary disease MESHD ( COPD MESHD) (RR=1.19, RR=2.68) both on the 14th and 18th day while elderly TRANS (AOR=2.56) and smokeless tobacco (SLT) (AOR=2.17) on the 28th day. Mortality risk factors included elderly TRANS (AOR=10.14), COPD MESHD (RR=5.93), and SLT (AOR=2.25) on the 14th day, and elderly TRANS (AOR=24.37) and COPD MESHD (RR=2.72) on the 28th day. The morbidity risk was higher with chronic kidney disease HP chronic kidney disease MESHD ( CKD MESHD) (RR=3.33) and chronic liver disease MESHD ( CLD MESHD) (RR=3.99) on the 28th day. The mortality risk was higher with coronary heart disease MESHD (RR=4.54) and CLD MESHD (RR=9.66) on the 14th while with diabetes mellitus HP diabetes mellitus MESHD (RR=3.08, RR=2.08), hypertension HP hypertension MESHD (RR=3.14, RR=2.30), CKD MESHD (RR=8.97, RR=2.71), and malignant diseases MESHD (RR=10.29) on both 14th and 28th day. We must espouse program interventions considering the morbidity and mortality risk factors to condense the aggressive outcomes of COVID-19.

    Effect of Physical Activity/Exercise Interventions on Immune Parameters, and Inflammatory Markers for Proxy Conditions Among Adults TRANS Prone to COVID-19: A Systematic Review Protocol

    Authors: Ebuka Miracle Anieto; Veronica Ebere Ogbodo; Ijeoma Blessing Nwadilibe; Omotoyosi Johnson Adu; Bouwien C.M. Smits-Engelsman; Jaleel Mohammed; Michael Ebe Kalu

    doi:10.21203/rs.3.rs-60112/v1 Date: 2020-08-15 Source: ResearchSquare

    BackgroundOlder individuals (over 60 years) with hypertension HP hypertension MESHD, diabetes MESHD, cardiovascular disease MESHD, chronic respiratory disease MESHD, and cancer MESHD are at the highest risk of contracting and dying from Coronavirus (COVID-19). Compromised immunity (both innate and adaptive) and increased inflammatory response HP (cytokine-storm syndrome) are predictors for high mortality among this population group. Exercise/physical activity seems to be a plausible way to decrease both the risk of transmission TRANS and mortality, and improve health outcomes among this population since there is no available treatment for COVID-19. The study will investigate the effectiveness of physical activity/exercise in improving the immune parameters and reducing the inflammatory biomarkers in proxy conditions that make individuals susceptible to COVID-19.MethodsThe Preferred Reporting Items for systematic reviews and Meta-Analyses Protocol (PRISMA-P) 2015 will guide this review. We will search ten databases (until August 2020) to include randomized control trials articles that explored the effectiveness of physical activity/exercise in improving immune parameters and reducing inflammatory biomarkers in proxy conditions ( hypertension HP hypertension MESHD, diabetes MESHD, cardiovascular disease MESHD, chronic respiratory disease MESHD and cancer MESHD). Two review authors will independently screen citations (title and abstract), extract data (using standardized forms), assess the risk of bias (using Cochrane risks of bias) and quality of data (using GRADE). Homogenous studies will be analyzed using the fixed-effect model of meta-analysis, while a narrative synthesis will be conducted for heterogeneous studies.DiscussionThere are no specific physical activity/exercise parameters (frequency, intensity, type of exercise and time- FITT) for interventionists to use when developing high-quality RCT for individuals vulnerable to COVID-19. Therefore, it is important to review the literature to identify and highlight the exercise FITT parameters that increase the immune outcomes and reduce inflammatory biomarkers for proxy conditions that make individuals susceptible to COVID-19. It is also important to identify the specific exercise regimen suitable and beneficial for each proxy group.Systematic review registrationPROSPERO CRD42020196907

    Trends in Covid-19 risk-adjusted mortality rates in a single health system

    Authors: Leora Horwitz; Simon A. Jones; Robert J. Cerfolio; Fritz Francois; Joseph Greco; Bret Rudy; Christopher M Petrilli; Ishan Paranjpe; Jessica K De Freitas; Tingyi Wanyan; Kipp W Johnson; Mesude Bicak; Eyal Klang; Young Joon Kwon; Anthony Costa; Shan Zhao; Riccardo Miotto; Alexander W Charney; Erwin Böttinger; Zahi A Fayad; Girish N Nadkarni; Fei Wang; Benjamin S Glicksberg; Laura J. Scott; Karen L. Mohlke; Kerrin S. Small

    doi:10.1101/2020.08.11.20172775 Date: 2020-08-14 Source: medRxiv

    Early reports showed high mortality from Covid-19; by contrast, the current outbreaks in the southern and western United States are associated with fewer deaths, raising hope that treatments have improved. However, in Texas for instance, 63% of diagnosed cases are currently under 50, compared to only 52% nationally in March-April. Current demographics in Arizona and Florida are similar. Therefore, whether decreasing Covid-19 mortality rates are a reflection of changing demographics or represent improvements in clinical care is unknown. We assessed outcomes over time in a single health system, accounting for changes in demographics and clinical factors. Methods We analyzed biweekly mortality rates for admissions between March 1 and June 20, 2020 in a single health system in New York City. Outcomes were obtained as of July 14, 2020. We included all hospitalizations with laboratory-confirmed Covid-19 disease. Patients with multiple hospitalizations (N=157, 3.3%) were included repeatedly if they continued to have laboratory-confirmed disease. Mortality was defined as in-hospital death MESHD or discharge to hospice care. Based on prior literature, we constructed a multivariable logistic regression model to generate expected risk of death MESHD, adjusting for age TRANS; sex; self-reported race and ethnicity; body mass index; smoking history; presence of hypertension HP hypertension MESHD, heart failure MESHD, hyperlipidemia HP hyperlipidemia MESHD, coronary artery disease MESHD, diabetes MESHD, cancer MESHD, chronic kidney disease HP chronic kidney disease MESHD, or pulmonary disease MESHD individually as dummy variables; and admission oxygen saturation, D-dimer, C reactive protein, ferritin, and cycle threshold for RNA detection. All data were obtained from the electronic health record. We then calculated the sum of observed and expected deaths in each two-week period and multiplied each period's observed/expected (O/E) risk by the overall average crude mortality to generate biweekly adjusted rates. We calculated Poisson control limits and indicated points outside the control limits as significantly different, following statistical process control standards. The NYU institutional review board approved the study and granted a waiver of consent. Results We included 4,689 hospitalizations, of which 4,661 (99.4%) had died or been discharged. The median age TRANS, and the proportion male TRANS or with any comorbidity decreased over time; median real-time PCR cycle threshold increased (indicating relatively less concentration of virus) (Table). For instance, median age TRANS decreased from 67 years in the first two weeks to 49 in the last two. Peak hospitalizations were during the fifth and sixth study weeks, which accounted for 40% of the hospitalizations. Median length of stay for patients who died or were discharged to hospice was 8 days (interquartile range, 4-16). Unadjusted mortality dropped each period, from 30.2% in the first two weeks to 3% in the last two weeks, with the last eight weeks being lower than the 95% control limits. Risk adjustment partially attenuated the mortality decline, but adjusted mortality rates in the second-to-last two weeks remained outside the control limits (Figure, Table). The O/E risk of mortality decreased from 1.07 (0.64-1.67) in the first two weeks to 0.39 (0.08-1.12) in the last two weeks. Discussion In this 16-week study of Covid-19 mortality at a single health system, we found that changes in demographics and severity of illness at presentation account for some, but not all, of the decrease in unadjusted mortality. Even after risk adjustment for a variety of clinical and demographic factors, mortality was significantly lower towards the end of the study period. Incremental improvements in outcomes are likely a combination of increasing clinical experience, decreasing hospital volume, growing use of new pharmacologic treatments (such as corticosteroids, remdesivir and anti-cytokine treatments), non-pharmacologic treatments (such as proning), earlier intervention, community awareness, and lower viral load exposure from increasing mask wearing and social distancing. It is also possible that earlier periods had a more virulent circulating strain. In summary, data from one health system suggest that Covid-19 remains a serious disease for high risk patients, but that outcomes may be improving.

    Observational Study on Clinical Features, Treatment and Outcome of COVID 19 in a tertiary care Centre in India- a retrospective case series

    Authors: Raja Bhattacharya; Rohini Ghosh; Manish Kulshrestha; Sampurna Chowdhury; Rishav Mukherjee; Indranil Ray; Lionel Tim Ee Cheng; Lynette Lin Ean Oon; Min Han Tan; Kian Sing Chan; Li Yang Hsu; Ramgyan Yadav; Ashish Timalsina; Chetan Nidhi Wagle; Brij Kumar Das; Ramesh Kunwar; Binaya Chalise; Deepak Raj Bhatta; Mukesh Adhikari; Michael Gale; Daniel J Campbell; David Rawlings; Marion Pepper

    doi:10.1101/2020.08.12.20170282 Date: 2020-08-14 Source: medRxiv

    ABSTRACT Objective: This study will attempt to explore the demographic profile and outcome in the patients receiving multidisciplinary, personalised approach including use of Broad Spectrum Antivirals - Ivermectin, anti-inflammatory and antioxidants roles of Statins and N-acetyl-cysteine along with Standard of Care (SOC) in hospitalised COVID19 patients in a tertiary care centre. Setting: Inpatient department Participants: 191 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections MESHD in the year 2020 between June 14- 28, 2020 Main outcome measures: The outcome of Interests are : Studying the demographic profile of COVID 19 cases Study the treatment outcomes in terms of death MESHD or discharge in patients receiving Ivermectin+N-acetyl-cysteine+Statin along with Standard of care. Results: 148 patients were included in the study. All of them had confirmed COVID19 infection MESHD by the rtPCR method. Average age TRANS of the patients was 57.57 years ( Range = 17 - 88), 49% were male TRANS, 51% female TRANS. 81% of the patients had at least one or more comorbidities. Most common comorbidities included diabetes MESHD( 32%), Hypertension HP Hypertension MESHD (27%), Ischaemic Heart Disease MESHD (8%). More comorbidities. The in hospital, Case Fatality Rate was therefore, 1.35 %. The remaining 144 were discharged from the facility after an average 12 days duration of stay. Conclusions: Triple therapy with ivermectin + atorvastatin + N-acetylcysteine can be an useful adjunct to standard of care. Keywords: SARS-CoV-2, COVID-19, outpatients, treatment, zinc, hydroxychloroquine, azithromycin

    Network reinforcement driven drug repurposing for COVID-19 by exploiting disease-gene-drug associations

    Authors: Yonghyun Nam; Jae-Seung Yun; Seung Mi Lee; Ji Won Park; Ziqi Chen; Brian Lee; Anurag Verma; Xia Ning; Li Shen; Dokyoon Kim; Eduardo Marquez-Garcia; Edda Sciutto; Jose Moreno-Rodriguez; Jose Omar Barreto-Rodriguez; Hazel Vazquez-Rojas; Gustavo Ivan Centeno-Saenz; Nestor Alvarado-Pena; Citlaltepetl Salinas-Lara; Carlos Sanchez-Garibay; Gabriela Hernandez-Molina; Criselda Mendoza-Milla; Andrea Dominguez; Julio Granados; Lula Mena-Hernandez; Luis Angel Perez-Buenfil; Guillermo Dominguez-Cheritt; Carlos Cabello-Gutierrez; Cesar Luna-Rivero; Jorge Salas-Hernandez; Patricio Santilla-Doherty; Justino Regalado; Angelica Hernandez-Martinez; Lorena Orozco; Ethel A. Garcia-Latorre; Carmen M. Hernandez-Cardenas; Shabaana A. Khader; Albert Zlotnik; Joaquin Zuniga

    doi:10.1101/2020.08.11.20173120 Date: 2020-08-14 Source: medRxiv

    Currently, the number of patients with COVID-19 has significantly increased. Thus, there is an urgent need for developing treatments for COVID-19. Drug repurposing, which is the process of reusing already-approved drugs for new medical conditions, can be a good way to solve this problem quickly and broadly. Many clinical trials for COVID-19 patients using treatments for other diseases have already been in place or will be performed at clinical sites in the near future. Additionally, patients with comorbidities such as diabetes mellitus HP diabetes mellitus MESHD, obesity HP obesity MESHD, liver cirrhosis MESHD cirrhosis HP, kidney diseases MESHD, hypertension HP hypertension MESHD, and asthma HP asthma MESHD are at higher risk for severe illness from COVID-19. Thus, the relationship of comorbidity disease with COVID-19 may help to find repurposable drugs. To reduce trial and error MESHD in finding treatments for COVID-19, we propose building a network-based drug repurposing framework to prioritize repurposable drugs. First, we utilized knowledge of COVID-19 to construct a disease-gene-drug network (DGDr-Net) representing a COVID-19-centric interactome with components for diseases, genes, and drugs. DGDr-Net consisted of 592 diseases, 26,681 human genes and 2,173 drugs, and medical information for 18 common comorbidities. The DGDr-Net recommended candidate repurposable drugs for COVID-19 through network reinforcement driven scoring algorithms. The scoring algorithms determined the priority of recommendations by utilizing graph-based semi-supervised learning. From the predicted scores, we recommended 30 drugs, including dexamethasone, resveratrol, methotrexate, indomethacin, quercetin, etc., as repurposable drugs for COVID-19, and the results were verified with drugs that have been under clinical trials. The list of drugs via a data-driven computational approach could help reduce trial-and-error in finding treatment for COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.